SSA
NKTR icon

Schonfeld Strategic Advisors’s Nektar Therapeutics NKTR Stock Holding History

Schonfeld Strategic Advisors’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-6,667
Closed -$1.8M – 2409
2021
Q3 		$1.8M Buy
+6,667
New +$1.6M 0.02% 752

Other funds holding NKTR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Schonfeld Strategic Advisors's NKTR Position: Q1 2026 in Review

Schonfeld Strategic Advisors opened a new position in Nektar Therapeutics (NKTR) in Q1 2026: 8,063 shares worth $580K. The stake represents ﹤0.01% of the portfolio and ranks #1327 among its holdings. This is a return to the name: Schonfeld Strategic Advisors previously reported a position in NKTR as recently as Q2 2025.

Schonfeld Strategic Advisors first reported a position in NKTR in Q3 2016 and has held it in 18 quarters since. The position peaked at $2.62M in Q2 2025. 215 funds tracked by Wall St. Rank hold NKTR as of Q1 2026.

  • Schonfeld Strategic Advisors held 8,063 shares of Nektar Therapeutics worth $580K as of Q1 2026.
  • Nektar Therapeutics was a new Schonfeld Strategic Advisors position in Q1 2026.
  • Nektar Therapeutics made up ﹤0.01% of Schonfeld Strategic Advisors's portfolio in Q1 2026, its #1327 holding.
  • Schonfeld Strategic Advisors first reported a position in Nektar Therapeutics in Q3 2016 and has held it in 18 quarters since.
  • Schonfeld Strategic Advisors's Nektar Therapeutics position peaked at $2.62M in Q2 2025.
  • 215 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q1 2026.

Based on Schonfeld Strategic Advisors's 13F filing for Q1 2026, filed 15 May 2026.